AtriCure (ATRC) Looks Repriced As Strong Q2 Earnings And Higher Guidance Reset The Story

AtriCure (ATRC) is back in focus after second quarter results showed revenue of US$153.6 million and net income of US$8.96 million, alongside updated 2026 guidance and fresh employee stock offering registrations.

See our latest analysis for AtriCure.

Those second quarter results and fresh 2026 guidance helped shift sentiment around AtriCure, with the stock posting a 43.5% 30 day share price return and a 21.67% 7 day share price return, although the 3 year total shareholder return is still down 29.39%, which suggests recent momentum is rebuilding from a weaker long term base.

If strong recent moves in AtriCure have you reassessing opportunities in medical technology, it can be useful to see what else is moving across healthcare focused screens such as 41 healthcare AI stocks.

Bulls point to AtriCure’s swing to profit and higher 2026 guidance, while bears highlight the weak 3 year return and fresh equity capacity. Which side does the current valuation and quality of earnings seem to support?

Most Popular Narrative: 14.6% Undervalued

The most followed valuation narrative for AtriCure sets a fair value of $47.00 against the latest close of $40.15, which implies upside in that framework and hinges on specific growth and profitability assumptions that investors may want to test for themselves.

Rapid revenue growth is supported by accelerated adoption of AtriCure's innovative, minimally invasive devices, such as the AtriClip FLEX Mini and cryoSPHERE MAX, which directly benefit from the global trend toward minimally invasive cardiac procedures and hospital prioritization of advanced surgical solutions. This increases both volumes and average selling prices, driving top-line expansion.

Read the complete narrative.

Curious what has to happen for that fair value to hold up. The narrative leans on brisk revenue expansion, rising margins and a rich future earnings multiple. The full story is in how those pieces fit together.

Result: Fair Value of $47.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the AtriCure narrative could still be tested if new pulsed field ablation competitors gain share faster than expected or if European pricing pressure intensifies.

Find out about the key risks to this AtriCure narrative.

Another View: Cash Flows Paint A Tougher Picture For AtriCure

The first narrative frames AtriCure as about 14.6% undervalued around a fair value of $47.00. The SWS DCF model comes to a very different result. On that approach, AtriCure at $40.15 screens as overvalued against an estimated future cash flow value of $0.73. Which lens do you trust more for long term decisions?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 57 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages so far from AtriCure, or a clear setup that just needs your own context. Act while the details are fresh in mind and weigh up the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond AtriCure?

If you only focus on AtriCure today, you could miss other stocks that better fit your goals. Use the Simply Wall Street Screener to compare fresh ideas side by side.

• Spot opportunities with strong quality at appealing prices by reviewing the 57 high quality undervalued stocks that stand out on both fundamentals and valuation checks.
• Strengthen your focus on capital preservation by scanning the 89 resilient stocks with low risk scores that score well on resilience and balance sheet metrics.
• Get ahead of the crowd by researching the screener containing 20 high quality undiscovered gems that combine solid financials with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com